Your browser doesn't support javascript.
loading
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Gao, Jianjun; Navai, Neema; Alhalabi, Omar; Siefker-Radtke, Arlene; Campbell, Matthew T; Tidwell, Rebecca Slack; Guo, Charles C; Kamat, Ashish M; Matin, Surena F; Araujo, John C; Shah, Amishi Y; Msaouel, Pavlos; Corn, Paul; Wang, Jianbo; Papadopoulos, John N; Yadav, Shalini S; Blando, Jorge M; Duan, Fei; Basu, Sreyashi; Liu, Wenbin; Shen, Yu; Zhang, Yuwei; Macaluso, Marc Daniel; Wang, Ying; Chen, Jianfeng; Zhang, Jianhua; Futreal, Andrew; Dinney, Colin; Allison, James P; Goswami, Sangeeta; Sharma, Padmanee.
Afiliação
  • Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. JGao1@mdanderson.org.
  • Navai N; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Alhalabi O; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Siefker-Radtke A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tidwell RS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Guo CC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Araujo JC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shah AY; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Corn P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Papadopoulos JN; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yadav SS; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Blando JM; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Duan F; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Basu S; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu W; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shen Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang Y; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Macaluso MD; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang Y; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dinney C; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allison JP; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Goswami S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Med ; 26(12): 1845-1851, 2020 12.
Article em En | MEDLINE | ID: mdl-33046869
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Urotélio / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Urotélio / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos